Attached files

file filename
EX-32.1 - CERTIFICATION - PLURISTEM THERAPEUTICS INCf10q0920ex32-1_pluristem.htm
EX-31.2 - CERTIFICATION - PLURISTEM THERAPEUTICS INCf10q0920ex31-2_pluristem.htm
EX-31.1 - CERTIFICATION - PLURISTEM THERAPEUTICS INCf10q0920ex31-1_pluristem.htm
EX-10.2 - GUARANTEE AGREEMENT BY AND AMONG THE EUROPEAN INVESTMENT BANK, PLURISTEM LTD. AN - PLURISTEM THERAPEUTICS INCf10q0920ex10-2_pluristem.htm
EX-10.1 - GUARANTEE AGREEMENT BY AND AMONG THE EUROPEAN INVESTMENT BANK, PLURISTEM THERAPE - PLURISTEM THERAPEUTICS INCf10q0920ex10-1_pluristem.htm
10-Q - QUARTERLY REPORT - PLURISTEM THERAPEUTICS INCf10q0920_pluristem.htm

Exhibit 32.2

 

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350

 

In connection with the Quarterly Report (the “Report”) of Pluristem Therapeutics Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof, I, Chen Franco-Yehuda, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. 1350, that to my knowledge:

 

1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date:  November 5, 2020  
By: /s/ Chen Franco-Yehuda
    Chen Franco-Yehuda
    Chief Financial Officer